Effects of hormone replacement therapy on endometrial histology in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial

JAMA

Volumn 275, Issue 5, 1996, Pages 370-375

  Judd, ^a   Meoane Sims, Irma ^b  

^a WYETH AYERST RESEARCH   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CURETTAGE; DOUBLE BLIND PROCEDURE; ENDOMETRIUM BIOPSY; ENDOMETRIUM HYPERPLASIA; ESTROGEN BLOOD LEVEL; ESTROGEN DEFICIENCY; ESTROGEN METABOLISM; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; HYSTERECTOMY; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0001657785     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.275.5.370     Document Type: Article

References (34)

1. Smith DC, Prentice E, Thompson DJ, Hermann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med. 1975;293:1164-1167.
2. Ziel HK, Hinkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975;293:1167-1170.
3. Maek TM, Pike MC, Henderson BE, et al. Estrogens and endometrial cancer in a retirement community. N Engl J Med. 1976;294:1262-1267.
4. Hulka BS, Fowler WC, Kaufman DG, et al. Estrogen and endometrial cancer: cases and two control groups from North Carolina. Am J Obstet Gynecol. 1980;137:92-101.
5. Shapiro S, Kelly JP, Rosenberg L, et al. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med. 1985;313:969-972.
6. Henderson BE. The cancer question: an overview of recent epidemiologic and retrospective data. Am J Obstet Gynecol. 1989;161:1869-1864.
7. Persson I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ. 1989;298:147-151.
8. Voigt LF, Weiss NS, Chu J, et al. Progestogen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet. 1991;338:274-277.
9. Brinton LA, Hoover RN, and The Endometrial Cancer Collaborative Group. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. Obstet Gynecol. 1993;81265-271.
10. Schiff I, Sela HK, Cramer D, et al. Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertil Steril. 1982;37:79-82.
11. Gelfand MM, Ferenczy A. A prospective 1-year study of estrogen and progestin in postmenopausal women: effects on the endometrium. Obstet Gynecol. 1989;74:398-402.
12. Woodruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxy-progesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol. 1994;170:1213-1223.
13. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273:199-208.
14. The Writing Group for the PEPI Trial. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial: rationale, design and conduct (I). J Controlled Clin Trials. 1995;16(suppl):3S-19S.
15. The Writing Group for the PEPI Trial. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial: the recruitment of postmenopausal women (II). J Controlled Clin Trials. 1995;16(suppl):20S-35S.
16. The Writing Group for the PEPI Trial. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial: physical and laboratory measurements (III). J Controlled Clin Trials. 1995;16(suppl):36S-53S.
17. The Writing Group for the PEPI Trial. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial: baseline characteristics of participants (IV). J Controlled Clin Trials. 1995;16(suppl):54S-72S.
18. Hendrickson M, Kempson R. Major Problems in Pathology. Philadelphia, Pa: WB Saunders; 1980;12:285-318. Major Problems in Pathology series.
19. Bush TL. Noncontraceptive estrogen use and risk of cardiovascular disease: an overview and critique of the literature. In: Korenmann SG, ed. The Menopause: Biological and Clinical Consequences of Ovarian Failure: Evolution and Management. Norwell, Mass: Serono Symposia; 1990:211-224.
20. Stampfer MJ, Colditz GA. Estrogen replacement and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
21. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
22. Kennedy DL, Baum C, Forbes MB. Noncontraception estrogens and progestins: use patterns over time. Obstet Gynecol. 1986;65:441-446.
23. Gibbons WE, Moyer DL, Lobo RA, Roy S, Mishell DR Jr. Biochemical and histologic effects of sequential estrogen/progestin therapy on the endometrium of postmenopausal women. Am J Obstet Gynecol. 1986;154:456-461.
24. Sturdee DW, Wade-Evans T, Paterson MEL, Thom M, Studd JWW. Relations between bleeding pattern, endometrium histology and estrogen treatment in menopausal women. BMJ. 1978;1:1575-1577.
25. Weinstein L. Efficacy of a continuous estrogen-progestin regimen in the menopausal patient. Obstet Gynecol. 1987;69:929-932.
26. Moorjani S, Dupont A, Labrie F, et al. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneous administration of estrogen alone or in cyclic association with utrogestan in menopausal women. J Clin Endocrinol Metabol. 1991;73:373-379.
27. Jensen J, Riis BJ, Strom V, Nilas L, Christiansen C. Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women. Am J Obstet Gynecol. 1987;156:66-71.
28. Gusberg SB. Precursors of corpus carcinoma: estrogens and adenomatous hyperplasia. Am J Obstet Gynecol. 1947;54:905-927.
29. Hall KV. Irregular hyperplasia of the endometrium. Acta Obstet Gynecol Scand. 1957;36:306-321.
30. Campbell PE, Barter RA. The significance of atypical endometrial hyperplasia. J Obstet Gynecol Br Commonw. 1961;68:668-672.
31. Wentz WB. Treatment of persistent endometrial hyperplasia with progestin. Am J Obstet Gynecol. 1966;96:999-1004.
32. Sherman AI, Brown S. The precursors of endometrial carcinoma. Am J Obstet Gynecol. 1979;135: 947-956.
33. Thom M, Whit PJ, Williams RM, et al. Prevention and treatment of endometrial disease in climacteric women receiving oestrogen therapy. Lancet 1978;1:455-457. metrial carcinoma. Am J Obstet Gynecol. 1979;135:947-956.
34. Thom M, Whit PJ, Williams RM, et al. Prevention and treatment of endometrial disease in climacteric women receiving oestrogen therapy. Lancet 1978;1:455-457. metrial carcinoma. Am J Obstet Gynecol. 1979;135:947-956.